SARC Business Meeting November 2005

Trial Update SARC 001 Gleevec –Closed to accrual –Outstanding data –Requests SARC 002 STS/gem-txt –Closed to accrual –Outstanding data –Requests

Trial Update SARC 003 bone/gem-txt IRB/Contracts –Mayo –MDAnderson 5 –NCI 3 –Ortho Hosp –Penn –Univ of MI 2 –Wash Cancer 1 –Yale 1 Contracts –Partners –Emory –Univ Florida Neither –MSKCC –Seattle –UCLA –Univ Toronto –Moffitt

Trial Update SARC 004 DFSP/Gleevec –University of Michigan –Seattle –Partners –MSKCC –MDAnderson

Trial Update SARC 005 –Adjuvant uterine/ gem/txt –IRB approval pending from MSKCC –Contracts –Database development –GOG SARC 006 –MPNST –DoD –Database development

Data capture –Web based –Ongoing training for data quality –CACR Center for the Advancement of Clinical Research Michigan Drug distribution –Centralized pharmacy –Reputation for quality –Biologics North Carolina Trial Support

Location Rented office space –Dominos Farms 24 Frank Lloyd Wright Dr Ann Arbor, MI

Employees Administrative assistant –Barb Thibert Accountant –Keith Locke Research Project Manager –Emily Hollenberg, RN, MPH

Finances Income (from inception 11/03) –$505,156 Expenses (from inception 11/03) –$192,202

Finances Income (by category) –Biannual meeting$ 15,000 –Donations$ 20,000 –Guideline Translation$ 25,000 –Primary Vascular$ 4,300 –Rosenfeld Symposia$ 50,000 –SARC 002$ 92,356 –SARC 003$ 40,000 ($ 78,000) –SARC 004$ 25,000 –Scientific Symposia$133,500 –Website Development$100,000 $505,156

Finances Expenses (by category) –Biannual meeting$ 17,871 –Operating expenses$ 49,650 –SARC 002$ 52,332 –SARC 003$ 40,229 –Scientific symposia$ 31,942 –Website development$ 180 $192,202

Executive Committee Monthly calls Review all trials Discuss protocols in development

Board of Directors Annual Meeting –November 18,2005

Development Subcommittee Members –Deborah Buks –David Marsh –Tim McCormick –Charles Nearberg Activities –Discuss strategies –Evaluate potential opportunities

Eugene and Maxine Rosenfeld David Marsh

The Silver Fox Club contributes 10 percent of its sales to helping those with sarcoma cancer, which has affected the founder’s wife. Out Fox Sarcoma Paul Corliss Ann Foote-Primary Vascular Sarcoma Fund

Development Meeting with Dr. Doroshow Utilize website RO1 application Continue to explore additional funding opportunities

Website Development Proposal from Altum/CommonHealth

Website Destination for sarcoma clinical trials Source of information –Physicians –Patients and families Emphasize credibility Call to action –Clinical trials –Support Link with other sites

Guideline Translation Nancy Leahy Laura Zyczynski Jenni Heaton Joan Giblin Kelly Scheu Linda Sohn Monica Davey Lauren Long Donna Bernstein Terri Armen Carolyn Hayes Denise Parker 7 pending

New Business Future directions –Developmental therapeutics –Launch website Maximize –Clinical trial awareness –Education –Outreach –Partnering